Form 4: Anebulo Pharmaceuticals Director and 10% Owner Acquires Shares in Private Placement

Aron R. English, a director and 10% owner of Anebulo Pharmaceuticals, along with 22NW Fund, LP, reports the acquisition of 10,101,010 shares of common stock at $0.99 per share through a private placement.

Summary

• Aron R. English, a director and 10% owner of Anebulo Pharmaceuticals, Inc. (ANEB), and 22NW Fund, LP, jointly filed a Form 4.
• The filing reports the acquisition of 10,101,010 shares of ANEB common stock by 22NW Fund, LP on December 23, 2024, at a price of $0.99 per share.
• Following the transaction, Mr. English indirectly beneficially owns 15,467,300 shares through 22NW Fund, LP, and 4,654,528 shares through Pharma Investors, LLC.
• The shares were acquired in connection with a private placement offering of the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the disclaimers and private placement aspect introduce some caution.

Positives

• Insider buying can sometimes be seen as a positive signal, indicating confidence in the company's future prospects.

Risks

• The filing includes disclaimers of beneficial ownership, except to the extent of pecuniary interest, which could indicate a complex ownership structure.
• The acquisition was part of a private placement, which may dilute existing shareholders' equity.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities. This particular filing reflects participation in a private placement, a common method for companies to raise capital.

Stakeholder Impact

• The private placement may dilute existing shareholders.
• The acquisition of shares by a director and significant owner could signal confidence to the market.

Key Dates